In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model: A pre-clinical study

Clinical and Experimental Rheumatology

Volumn 28, Issue 2, 2010, Pages 176-185

  Triantaphyllopoulos, Kostas ^a   Madden, Leigh ^a   Rioja, Inma ^b   Essex, David ^a   Buckton, Jacky ^b   Malhotra, Rajneesh ^b   Ray, Keith ^b   Binks, Michael ^b   Paleolog, Ewa M ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Arthritis; Cytokine; Joint; Mouse; p38 MAP kinase

Indexed keywords

COLLAGEN; GSK 678361; GW 856553 X; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL MIGRATION; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DBA 1 MOUSE; DISEASE MODEL; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; JOINT DESTRUCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN; VALIDATION PROCESS;

ACUTE DISEASE; ANIMALS; ARTHRITIS, EXPERIMENTAL; CHEMOKINE CCL2; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MICE; MICE, INBRED DBA; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; RECURRENCE; UMBILICAL VEINS;

EID: 77952751985     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. FAROOQ A, ZHOU MM: Structure and regulation of MAPK phosphatases. Cell Signal 2004, 16: 769-779
2. KAMINSKA B: MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005, 1754: 253-262
3. BAINBRIDGE J, MADDEN L, ESSEX D, BINKS M, MALHOTRA R, PALEOLOG EM: Methionine aminopeptidase-2 blockade reduces chronic collagen-induced arthritis: potential role for angiogenesis inhibition. Arthritis Res Ther 2007, 9: R127.
4. MALFAIT AM, WILLIAMS RO, MALIK AS, MAINI RN, FELDMANN M: Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis Rheum 2001, 44: 1215-1224
5. ASTON NM, BAMBOROUGH P, BUCKTON JB et al.: p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J Med Chem 2009; 52: 6257-6269
6. MILLER EJ: Structural studies on cartilage collagen employing limited cleavage and solubilization with pepsin. Biochemistry 1972, 11: 4903-4909
7. WILLIAMS RO, FELDMANN M, MAINI RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992, 89: 9784-9788
8. WILLIAMS RO, MASON LJ, FELDMANN M, MAINI RN: Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994, 91: 2762-2766
9. WILLIAMS RO, GHRAYEB J, FELDMANN M, MAINI RN: Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995, 84: 433-439
10. MIOTLA J, MACIEWICZ R, KENDREW J, FELDMANN M, PALEOLOG E: Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000, 80: 1195-1205
11. WILLIAMS RO, MARINOVA-MUTAFCHIEVA L, FELDMANN M, MAINI RN: Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J Immunol 2000, 165: 7240-7245
12. AFUWAPE A, FELDMANN M, PALEOLOG E: Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Therapy 2003, 10: 1950-1960
13. SUMARIWALLA P, CAO Y, WU H, FELDMANN M, PALEOLOG E: The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 2003, 5:R32-R39.
14. SUMARIWALLA PF, JIN P, ZHANG J et al.: Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen-induced arthritis. Arthritis Rheum 2008, 58: 3071-3080
15. HOLMDAHL R, JANSSON L, LARSSON E, RUBIN K, KLARESKOG L: Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum 1986, 29:106-113
16. GROSJEAN J, KIRIAKIDIS S, REILLY K, FELDMANN M, PALEOLOG E: Vascular endothelial growth factor signalling in endothelial cell survival: A role for NFkappaB. Biochem Biophys Res Commun 2006, 340: 984-994
17. BADGER AM, BRADBEER JN, VOTTA B, LEE JC, ADAMS JL, GRISWOLD DE: Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996, 279: 1453-1461
18. BARONE FC, IRVING EA, RAY AM et al.: SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther 2001, 296: 312-321
19. DE DIOS A, SHIH C, LOPEZ DE URALDE B et al.: Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. J Med Chem 2005, 48: 2270-2273
20. DUMAS J, HATOUM-MOKDAD H, SIBLEY RN et al.: Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor. Bioorg Med Chem Lett 2002, 12: 1559-1562
21. REVESZ L, BLUM E, DI PADOVA FE et al.: Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. Bioorg Med Chem Lett 2004, 14: 3595-3599
22. WADA Y, NAKAJIMA-YAMADA T, YAMADA K et al.: R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models. Eur J Pharmacol 2005, 506: 285-295
23. FRANTZ B, KLATT T, PANG M et al.: The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 1998; 37: 13846-13853
24. BRANGER J, VAN DEN BLINK B, WEIJER S et al.: Anti-inflammatory effects of a p38 mitogen- activated protein kinase inhibitor during human endotoxemia. J Immunol 2002, 168: 4070-4077
25. FIJEN JW, ZIJLSTRA JG, DE BOER P et al.: Suppression of the clinical and cytokine hresponse to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 2001, 124: 16-20.
26. BIRRELL MA, WONG S, MCCLUSKIE K et al.: Second-generation inhibitors demonstrate the involvement of p38 mitogen-activated protein kinase in post-transcriptional modulation of inflammatory mediator production in human and rodent airways. J Pharmacol Exp Ther 2006, 316: 1318-1327
27. DUAN W, CHAN JH, MCKAY K et al.: Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 2005, 171: 571-578
28. TRIFILIEFF A, KELLER TH, PRESS NJ et al.: CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br J Pharmacol 2005, 144: 1002-1010
29. UNDERWOOD DC, OSBORN RR, KOTZER CJ et al.: SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 2000, 293: 281-288
30. DODELLER F, SCHULZE-KOOPS H: The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells. Arthritis Res Ther 2006, 8: 205.
31. BARSYTE-LOVEJOY D, GALANIS A, SHARROCKS AD: Specificity determinants in MAPK signaling to transcription factors. J Biol Chem 2002, 277: 9896-9903
32. GALE EA, BINGLEY PJ, EMMETT CL, COLLIER T: European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363: 925-931
33. PERETTO I, RADAELLI S, PARINI C et al.: Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J Med Chem 2005, 48: 5705-5720
34. LEE MR, DOMINGUEZ C: MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 2005, 12: 2979-2994